Meeting
2016 Gastrointestinal Cancers Symposium
Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Authors
Andrea Wang-Gillam
Washington University in St. Louis, St. Louis, MO
Andrea Wang-Gillam , Chung-Pin Li , Gyorgy Bodoky , Andrew Dean , Yang-Shen Shan , Gayle S. Jameson , Teresa Macarulla , Kyung-Hun Lee , David Cunningham , Jean-Frédéric Blanc , Richard Hubner , Chang-Fang Chiu , Gilberto Schwartsmann , Jens T Siveke , Fadi S. Braiteh , Victor M. Moyo , Bruce Belanger , Eliel Bayever , Daniel D. Von Hoff , Li-Tzong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 417)
DOI
10.1200/jco.2016.34.4_suppl.417
Abstract #
417
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
First Author: Andrea Wang-Gillam
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2016 Gastrointestinal Cancers Symposium
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Li-Tzong Chen
Poster
2015 Gastrointestinal Cancers Symposium
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Li-Tzong Chen